NeuroMetrix, Inc. stock is down -82.4% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 19 December’s closed higher than November.
NeuroMetrix, Inc. engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy. Quell, a wearable device for symptomatic relief and management of chronic pain.